Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Brain : a journal of neurology

• Publication date

  2004-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/BRAIN/AWH290PMID 15329355
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Structural Organization of the Readily Releasable Pool of Synaptic Vesicles

  2004cited by this paper
• Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.

  2004influential reference
• Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.

  2004cited by this paper
• Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms

  2004cited by this paper
• VMAT2 binding is elevated in dopa‐responsive dystonia: Visualizing empty vesicles by PET

  2003cited by this paper
• Mechanisms of motor complications in treatment of Parkinson's disease.

  2003cited by this paper
• In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone.

  2003cited by this paper
• Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease

  2001influential reference
• Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition

  2001influential reference
• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

  2001influential reference
• The long-term response to levodopa in dopa-responsive dystonia.

  2001cited by this paper
• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.

  2001influential reference
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.

  1999cited by this paper
• The Biochemical Basis of Neuropharmacology, 7th ed

  1998cited by this paper
• Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

  1997cited by this paper
• In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

  1997cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.

  1996cited by this paper
• Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys

  1996cited by this paper
• Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET

  1996cited by this paper
• Do parkinsonian symptoms and levodopa‐induced dyskinesias start in the foot?

  1994cited by this paper
• Motor response complications and the function of striatal efferent systems

  1993cited by this paper
• Criteria for diagnosing Parkinson's disease

  1992cited by this paper
• Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

  1991cited by this paper
• Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism.

  1991cited by this paper
• Young‐onset Parkinson's disease

  1991cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990cited by this paper
• Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

  1990cited by this paper
• Practical statistics for medical research

  1990influential reference
• Levodopa‐induced dyskinesia

  1990cited by this paper
• Pathogenesis of dyskinesias in parkinson's disease

  1989influential reference
• Analysis of emission tomographic scan data: limitations imposed by resolution and background.

  1984cited by this paper
• Fluctuations of disability in Parkinson's disease – clinical aspects

  1981cited by this paper
• Parkinson's disease: a clinical review.

  1974cited by this paper
• Monoamines noyaux gris centraux et syndorme de Parkinson

  1971cited by this paper
• The Biochemical Basis of Neuropharmacology

  1971cited by this paper

• Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson’s disease

  2026cites this paper
• State-dependent modulation of spiny projection neurons controls levodopa-induced dyskinesia in a mouse model of Parkinson’s disease

  2025cites this paper
• Design, synthesis, investigation, and biological activity assessments of n-allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents

  2025cites this paper
• State-dependent modulation of spiny projection neurons controls levodopa-induced dyskinesia in a mouse model of Parkinson’s disease

  2025cites this paper
• Nonmotor fluctuations in Parkinson’s disease: impact on caregiving and quality of life

  2025cites this paper
• Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

  2025cites this paper
• A generalized framework for in vivo detection of dopamine release using positron emission tomography

  2025cites this paper
• Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease

  2025cites this paper
• Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

  2025cites this paper
• The Roles of Neuroinflammation in l‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches

  2025cites this paper
• Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias

  2024cites this paper
• Impact of Physical Exercise on Levodopa Therapy Across Parkinson’s Disease Stages

  2024cites this paper
• Are impulsive compulsive behaviors associated with levodopa-induced dyskinesia? A Brazilian cross-sectional study.

  2024cites this paper
• Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

  2024cites this paper
• Epigenetic Regulation of Gene Expression in the Development of Neurodegenerative Diseases: A Narrative Review

  2023cites this paper
• Multimodal imaging study of the 5-HT1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia

  2023cites this paper
• Neuroplasticity in levodopa-induced dyskinesias: an overview on pathophysiology and therapeutic targets.

  2023cites this paper
• Novel voxelwise residual analysis of [11C]raclopride PET data improves detection of low-amplitude dopamine release

  2023cites this paper
• Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.

  2023cites this paper
• PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

  2023cites this paper
• Chronic H3R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D1R mRNA expression in 6-hydroxydopamine-lesioned male rats

  2023cites this paper
• Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

  2023cites this paper
• Translational molecular imaging and drug development in Parkinson’s disease

  2023cites this paper
• Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson's disease.

  2023cites this paper
• Remote Programming in Patients With Parkinson's Disease After Deep Brain Stimulation: Safe, Effective, and Economical

  2022cites this paper
• Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

  2022cites this paper
• Modulating Microglia/Macrophage Activation by CDNF Promotes Transplantation of Fetal Ventral Mesencephalic Graft Survival and Function in a Hemiparkinsonian Rat Model

  2022cites this paper
• Autopallidotomy: From Colloquial Term to Scientific Theory

  2022cites this paper
• Tackling the challenges of developing microneedle-based electrochemical sensors

  2022cites this paper
• Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties.

  2022cites this paper
• Striatal synaptic dysfunction in dystonia and levodopa-induced dyskinesia.

  2022cites this paper
• Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias.

  2022cites this paper
• The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats

  2022cites this paper
• Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease

  2022cites this paper
• Dopamine neuron stimulation induces context-dependent abnormal involuntary movements in healthy rats

  2022cites this paper
• The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.

  2022cites this paper
• Molecular Sciences L-DOPA in Parkinson’s Disease: Looking at the ”False” Neurotransmitters and Their Meaning

  2021cites this paper
• Role of the Dopaminergic System in the Striatum and Its Association With Functional Recovery or Rehabilitation After Brain Injury

  2021cites this paper
• Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia

  2021cites this paper
• Parkinson’s Disease

  2021cites this paper
• Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs

  2021cites this paper
• Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease

  2021cites this paper
• Simultaneous Measurement of Striatal Dopamine and Hydrogen Peroxide Transients Associated with L-DOPA Induced Rotation in Hemiparkinsonian Rats

  2021cites this paper
• Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson’s disease—a meta-analysis

  2021cites this paper
• Parkinson ' s Disease with Device , Diary , or in Disguise . Dyskinesia reduction , motor state evaluation , and workforce participation among persons with Parkinson ' s disease

  2021cites this paper
• Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia

  2021cites this paper
• Neurology Grand Rounds: Changing gears - DBS for dopaminergic desensitization in Parkinson's disease?

  2021cites this paper
• Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.

  2021cites this paper
• Synergistic Effect of Serotonin 1A and Serotonin 1B/D Receptor Agonists in the Treatment of L-DOPA-Induced Dyskinesia in 6-Hydroxydopamine-Lesioned Rats

  2021cites this paper
• Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism

  2021cites this paper
• Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum

  2021cites this paper
• Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.

  2021cites this paper
• Wirkfluktuationen und Dyskinesien optimal entgegensteuern

  2020cites this paper
• Cognitive flexibility in humans and other laboratory animals

  2020cites this paper
• The Vasomotor Response to Dopamine Is Altered in the Rat Model of l‐dopa‐Induced Dyskinesia

  2020cites this paper
• Correlates of Psychological Distress in Patients with Parkinson's Disease During the COVID‐19 Outbreak

  2020cites this paper
• The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

  2020cites this paper
• Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia

  2020cites this paper
• Precisely-timed dopamine signals establish distinct kinematic representations of skilled movements

  2020cites this paper
• GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.

  2020cites this paper
• Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinson's disease.

  2020cites this paper
• Precisely timed dopamine signals establish distinct kinematic representations of skilled movements

  2020cites this paper
• High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.

  2020cites this paper
• Infusion Therapies for Parkinson’s Disease

  2020cites this paper
• MRI of Motor and Nonmotor Therapy‐Induced Complications in Parkinson's Disease

  2020cites this paper
• Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson’s Disease: Pulsatile versus Continuous Dopaminergic Stimulation

  2020cites this paper
• Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review

  2020cites this paper
• D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

  2020cites this paper
• Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease

  2020cites this paper
• Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.

  2020cites this paper
• Dopamine Transporter Density in de novo Parkinson’s Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias

  2019cites this paper
• CLINICAL TRIAL HIGHLIGHTS – DYSKINESIA

  2019cites this paper
• Molecular Imaging of the Dopamine Transporter

  2019cites this paper
• An electrochemical biosensor based on double molecular recognition for selective monitoring of cerebral dopamine dynamics at 4 min interval

  2019cites this paper
• Nicotinic acetylcholine receptors in experimental models of Parkinson’s disease and levodopa-induced dyskinesia : focus on α5 subunit-containing receptors

  2019cites this paper
• The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases

  2019cites this paper
• The Locus coeruleus in Parkinson’s disease - from basic research to new translational perspectives -

  2019cites this paper
• Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats

  2019cites this paper
• Allelic variant in SLC6A3 rs393795 affects cerebral regional homogeneity and gait dysfunction in patients with Parkinson’s disease

  2019cites this paper
• Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

  2019cites this paper
• Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients

  2019cites this paper
• Eltoprazine prevents levodopa‐induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate

  2019cites this paper
• Parkinson’s Disease Dyskinesias Possibly Relate to Greater Dopamine Transporter Losses in the Putamen Over Time

  2019cites this paper
• Highly Uniform, Flexible Microelectrodes Based on the Clean Single-Walled Carbon Nanotube Thin Film with High Electrochemical Activity.

  2019cites this paper
• L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning

  2019cites this paper
• Risk Factors and Metabolism of Different Brain Regions by Positron Emission Tomography in Parkinson Disease with Disabling Dyskinesia.

  2019cites this paper
• PET Imaging in Movement Disorders.

  2018cites this paper
• Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats

  2018cites this paper
• Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts

  2018cites this paper
• Dyskinesias and levodopa therapy: why wait?

  2018cites this paper
• Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease

  2018cites this paper
• The role of serotonergic and dopaminergic mechanisms and their interaction in Levodopa-induced dyskinesias

  2018cites this paper
• Cortical response to levodopa in Parkinson's disease patients with dyskinesias

  2018cites this paper
• Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

  2018cites this paper
• L‐DOPA for Parkinson's disease—a bittersweet pill

  2018cites this paper
• Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

  2018cites this paper
• The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective

  2018cites this paper
• UPSALIENSIS UPPSALA 2018 Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1437 New Approaches for Levodopa Treatment in Parkinson ’ s Disease MARINA

  2018cites this paper
• „Medikamentös ausbehandelte Fluktuationen“ trotz „optimierter peroraler/transdermaler Therapie“ bei Morbus Parkinson: Versuch einer pragmatischen Definition

  2018cites this paper
• Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse

  2018cites this paper